These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
577 related articles for article (PubMed ID: 22506086)
1. In vitro and in vivo efficacy of ether lipid edelfosine against Leishmania spp. and SbV-resistant parasites. Varela-M RE; Villa-Pulgarin JA; Yepes E; Müller I; Modolell M; Muñoz DL; Robledo SM; Muskus CE; López-Abán J; Muro A; Vélez ID; Mollinedo F PLoS Negl Trop Dis; 2012; 6(4):e1612. PubMed ID: 22506086 [TBL] [Abstract][Full Text] [Related]
2. Mitochondria and lipid raft-located FOF1-ATP synthase as major therapeutic targets in the antileishmanial and anticancer activities of ether lipid edelfosine. Villa-Pulgarín JA; Gajate C; Botet J; Jimenez A; Justies N; Varela-M RE; Cuesta-Marbán Á; Müller I; Modolell M; Revuelta JL; Mollinedo F PLoS Negl Trop Dis; 2017 Aug; 11(8):e0005805. PubMed ID: 28829771 [TBL] [Abstract][Full Text] [Related]
3. Ex vivo host and parasite response to antileishmanial drugs and immunomodulators. Gonzalez-Fajardo L; Fernández OL; McMahon-Pratt D; Saravia NG PLoS Negl Trop Dis; 2015 May; 9(5):e0003820. PubMed ID: 26024228 [TBL] [Abstract][Full Text] [Related]
4. Effect of the lysophospholipid analogues edelfosine, ilmofosine and miltefosine against Leishmania amazonensis. Santa-Rita RM; Henriques-Pons A; Barbosa HS; de Castro SL J Antimicrob Chemother; 2004 Oct; 54(4):704-10. PubMed ID: 15329361 [TBL] [Abstract][Full Text] [Related]
5. In vivo activity of perifosine against Leishmania amazonensis. Cabrera-Serra MG; Valladares B; Piñero JE Acta Trop; 2008 Oct; 108(1):20-5. PubMed ID: 18801328 [TBL] [Abstract][Full Text] [Related]
6. Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B. Escobar P; Matu S; Marques C; Croft SL Acta Trop; 2002 Feb; 81(2):151-7. PubMed ID: 11801222 [TBL] [Abstract][Full Text] [Related]
7. Aspects of the cytological activity of edelfosine, miltefosine, and ilmofosine in Leishmania donovani. Azzouz S; Maache M; Dos Santos MF; Sarciron ME; Petavy AF; Osuna A J Parasitol; 2006 Oct; 92(5):877-83. PubMed ID: 17152926 [TBL] [Abstract][Full Text] [Related]
8. Pterocarpanquinone LQB-118 induces apoptosis in Leishmania (Viannia) braziliensis and controls lesions in infected hamsters. Costa L; Pinheiro RO; Dutra PM; Santos RF; Cunha-Júnior EF; Torres-Santos EC; da Silva AJ; Costa PR; Da-Silva SA PLoS One; 2014; 9(10):e109672. PubMed ID: 25340550 [TBL] [Abstract][Full Text] [Related]
9. Resveratrol analogues present effective antileishmanial activity against promastigotes and amastigotes from distinct Leishmania species by multitarget action in the parasites. Antinarelli LMR; Meinel RS; Coelho EAF; da Silva AD; Coimbra ES J Pharm Pharmacol; 2019 Dec; 71(12):1854-1863. PubMed ID: 31595530 [TBL] [Abstract][Full Text] [Related]
10. Photodynamic therapy offers a novel approach to managing miltefosine-resistant cutaneous leishmaniasis. Cabral FV; Riahi M; Persheyev S; Lian C; Cortez M; Samuel IDW; Ribeiro MS Biomed Pharmacother; 2024 Aug; 177():116881. PubMed ID: 38917757 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of oleylphosphocholine (OlPC) in a laboratory model of visceral leishmaniasis. Fortin A; Hendrickx S; Yardley V; Cos P; Jansen H; Maes L J Antimicrob Chemother; 2012 Nov; 67(11):2707-12. PubMed ID: 22782488 [TBL] [Abstract][Full Text] [Related]
12. The HSP90 inhibitor 17-AAG potentiates the antileishmanial activity of the ether lipid edelfosine. Varela-M RE; Mollinedo-Gajate C; Muro A; Mollinedo F Acta Trop; 2014 Mar; 131():32-6. PubMed ID: 24299925 [TBL] [Abstract][Full Text] [Related]
13. Novel organic salts based on quinoline derivatives: The in vitro activity trigger apoptosis inhibiting autophagy in Leishmania spp. Calixto SL; Glanzmann N; Xavier Silveira MM; da Trindade Granato J; Gorza Scopel KK; Torres de Aguiar T; DaMatta RA; Macedo GC; da Silva AD; Coimbra ES Chem Biol Interact; 2018 Sep; 293():141-151. PubMed ID: 30098941 [TBL] [Abstract][Full Text] [Related]
14. An effective in vitro and in vivo antileishmanial activity and mechanism of action of 8-hydroxyquinoline against Leishmania species causing visceral and tegumentary leishmaniasis. Costa Duarte M; dos Reis Lage LM; Lage DP; Mesquita JT; Salles BC; Lavorato SN; Menezes-Souza D; Roatt BM; Alves RJ; Tavares CA; Tempone AG; Coelho EA Vet Parasitol; 2016 Feb; 217():81-8. PubMed ID: 26827866 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of antileishmanial drugs activities in an ex vivo model of leishmaniasis. Terreros MJS; de Luna LAV; Giorgio S Parasitol Int; 2019 Aug; 71():163-166. PubMed ID: 30991111 [TBL] [Abstract][Full Text] [Related]
16. Meglumine antımoniate-TiO2@Ag nanoparticle combinations reduce toxicity of the drug while enhancing its antileishmanial effect. Abamor ES; Allahverdiyev AM; Bagirova M; Rafailovich M Acta Trop; 2017 May; 169():30-42. PubMed ID: 28111133 [TBL] [Abstract][Full Text] [Related]
17. Ether--lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether--lipid analogues in Leishmania. Lux H; Heise N; Klenner T; Hart D; Opperdoes FR Mol Biochem Parasitol; 2000 Nov; 111(1):1-14. PubMed ID: 11087912 [TBL] [Abstract][Full Text] [Related]
18. Novel approach to in vitro drug susceptibility assessment of clinical strains of Leishmania spp. Fernández O; Diaz-Toro Y; Valderrama L; Ovalle C; Valderrama M; Castillo H; Perez M; Saravia NG J Clin Microbiol; 2012 Jul; 50(7):2207-11. PubMed ID: 22518860 [TBL] [Abstract][Full Text] [Related]